Get the Stockscreener App
0.3468
4.12%
-0.0149
After Hours:
.34
-0.0068
-1.96%
Aspire Biopharma Holdings Inc stock is traded at $0.3468, with a volume of 965.06K.
It is down -4.12% in the last 24 hours and down -9.64% over the past month.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
See More
Previous Close:
$0.3617
Open:
$0.3568
24h Volume:
965.06K
Relative Volume:
0.05
Market Cap:
$17.18M
Revenue:
-
Net Income/Loss:
$-27.39M
P/E Ratio:
-0.2064
EPS:
-1.6803
Net Cash Flow:
$-2.09M
1W Performance:
-22.05%
1M Performance:
-9.64%
6M Performance:
+2.00%
1Y Performance:
+0.00%
1-Day Range:
$0.3242
$0.3599
1-Week Range:
$0.3242
$0.4691
52-Week Range:
$0.2012
$2.10
Aspire Biopharma Holdings Inc Stock (ASBP) Company Profile
Name
Aspire Biopharma Holdings Inc
Sector
Industry
Phone
561-704-8527
Address
194 CANDELARO DRIVE, #233, HUMACAO
Compare ASBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASBP
Aspire Biopharma Holdings Inc
|
0.3468 | 17.91M | 0 | -27.39M | -2.09M | -1.6803 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.67 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
628.00 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
423.47 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.48 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
182.77 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Aspire Biopharma Holdings Inc Stock (ASBP) Latest News
A look into Aspire Biopharma Holdings Inc (ASBP)’s deeper side - setenews.com
Penny Stocks To Watch TodayOctober 2nd - MarketBeat
What drives Aspire Biopharma Holdings Inc stock priceSell Signals and Alerts & Rapid Portfolio Investment - earlytimes.in
Aspire Biopharma Holdings, Inc., Announces Last Patient Dosed in Phase 1 Clinical Trial of its Oral Transmucosal Fast-Acting High-Dose Aspirin Formulation - The Daily Jeffersonian
Working capital per share of Aspire Biopharma Holdings, Inc. – NASDAQ:ASBP - TradingView
Aspire Biopharma Faces Nasdaq Delisting Notice - MSN
Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall By Investing.com - Investing.com Australia
Aspire Biopharma faces potential Nasdaq delisting after compliance shortfall - Investing.com India
Aspire Looks To Key Milestones For Sublingual Aspirin And Semaglutide - insights.citeline.com
Aspire Biopharma Holdings Inc Equity Warrant Stock Analysis and ForecastEarnings Call Summaries & High Profit Market Ideas - earlytimes.in
Aspire Biopharma files omnibus patent for sublingual delivery tech By Investing.com - Investing.com Canada
Is Aspire Biopharma Holdings Inc a good long term investmentResistance Zone Identification & Free Stock Predictions and Analysis - earlytimes.in
Aspire Biopharma files omnibus patent for sublingual delivery tech - Investing.com
Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform - ACCESS Newswire
Penny Stocks To Watch Today – October 2nd - Defense World
Aspire Biopharma Hldgs Stock Price, Quotes and Forecasts | NASDAQ:ASBP - Benzinga
Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity ConferenceOctober 8-9, 2025 - ACCESS Newswire
Why Actelis Networks Shares Are Trading Higher By Over 40%; Here Are 20 Stocks Moving Premarket - Benzinga
Crude Oil Down 2%; Aspire Biopharma Shares Spike Higher - inkl
Stock Market Update: Nasdaq's Most Active Stocks on Oct 2, 2025News and Statistics - IndexBox
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results - Benzinga
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - Benzinga
Aspire Biopharma outlines pipeline milestones for drug delivery tech By Investing.com - Investing.com Australia
Aspire Biopharma outlines pipeline milestones for drug delivery tech - Investing.com
Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication - ACCESS Newswire
Breakthrough 2-Minute Heart Attack Treatment: Aspire's Sublingual Aspirin Beats Standard Tablets in Clinical Tests - Stock Titan
Is There Hidden Value in Modern Engineering and Projects Limiteds Business ModelQuarterly Earnings Review & Double Digit Trading Ideas - earlytimes.in
What drives Aspire Biopharma Holdings Inc Equity Warrant stock priceCandlestick Trading Patterns & Best Stocks For Explosive Growth - earlytimes.in
What analysts say about Aspire Biopharma Holdings Inc stockShort-Term Trading Alerts & Free Powerful Profit Generation - earlytimes.in
What analysts say about Aspire Biopharma Holdings Inc Equity Warrant stockResistance Zone Identification & Register for the Next Free Workshop - earlytimes.in
How Star Equity Holdings Inc. (FDV0) stock trades after earningsIPO Watch & Reliable Breakout Forecasts - newser.com
Aspire Biopharma Holdings Inc Stock Analysis and ForecastPrice-to-Earnings Ratio Insights & Minimal Investment Capital - earlytimes.in
Aspire Biopharma completes $1 million funding tranche and changes auditor By Investing.com - Investing.com Australia
Aspire Biopharma completes $1 million funding tranche and changes auditor - Investing.com
Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack) - Detroit Free Press
Aspire Biopharma Holdings, Inc. Announces CEO Transition - Foster's Daily Democrat
Aspire Biopharma files to sell 147.18M shares of common stock for holders - MSN
Aspire Biopharma Enlists Fitness Influencers To Promote Pre-Workout Product - Net Influencer
Aspire Biopharma secures initial order for preworkout supplement, part of agreement with SupraNatural - MSN
Aspire Biopharma Holdings Inc (NASDAQ: ASBP) 8.11% Incline Turns Away Investor Interest In Company’s Stock - stocksregister.com
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product - ACCESS Newswire
Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product | FinancialContent - FinancialContent
2-Minute Energy Boost: Aspire's BUZZ BOMB Teams with UFC Champion to Disrupt Pre-Workout Market - Stock Titan
Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement - ACCESS Newswire
2 Million Unit Production Order: Aspire Biopharma Scales BUZZ BOMB Pre-Workout in $27.9B Market - Stock Titan
Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement - Fall River Herald News
Can volume confirm reversal in NCR Voyix CorporationEarnings Overview Report & Safe Investment Capital Preservation Plans - newser.com
Aspire Biopharma Holdings Inc Stock (ASBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.45%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):